225 related articles for article (PubMed ID: 30963691)
1. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
[TBL] [Abstract][Full Text] [Related]
4. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Ikeda M; Morimoto M; Tajimi M; Inoue K; Benhadji KA; Lahn MMF; Sakai D
Invest New Drugs; 2019 Feb; 37(1):118-126. PubMed ID: 29995286
[TBL] [Abstract][Full Text] [Related]
7. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
[TBL] [Abstract][Full Text] [Related]
8. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
[TBL] [Abstract][Full Text] [Related]
9. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.
Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G
Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
12. A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.
Reiss KA; Wattenberg MM; Damjanov N; Prechtel Dunphy E; Jacobs-Small M; Lubas MJ; Robinson J; Dicicco L; Garcia-Marcano L; Giannone MA; Karasic TB; Furth EE; Carpenter EL; Wojcieszynski AP; Vonderheide RH; Beatty GL; Ben-Josef E
Mol Cancer Ther; 2021 Feb; 20(2):389-397. PubMed ID: 33268571
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Melisi D; Oh DY; Hollebecque A; Calvo E; Varghese A; Borazanci E; Macarulla T; Merz V; Zecchetto C; Zhao Y; Gueorguieva I; Man M; Gandhi L; Estrem ST; Benhadji KA; Lanasa MC; Avsar E; Guba SC; Garcia-Carbonero R
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688022
[TBL] [Abstract][Full Text] [Related]
14. High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Lin TH; Shao YY; Chan SY; Huang CY; Hsu CH; Cheng AL
Clin Cancer Res; 2015 Aug; 21(16):3678-84. PubMed ID: 25977342
[TBL] [Abstract][Full Text] [Related]
15. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.
Hammad S; Cavalcanti E; Werle J; Caruso ML; Dropmann A; Ignazzi A; Ebert MP; Dooley S; Giannelli G
Arch Toxicol; 2018 Jul; 92(7):2297-2309. PubMed ID: 29808285
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
17. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
Liu X; Yu M; Chen Y; Zhang J
Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
[TBL] [Abstract][Full Text] [Related]
18. A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner.
Ishigami I; Shuwari N; Kaminade T; Mizuguchi H; Sakurai F
Anticancer Res; 2021 May; 41(5):2431-2440. PubMed ID: 33952468
[TBL] [Abstract][Full Text] [Related]
19. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
[TBL] [Abstract][Full Text] [Related]
20. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
